Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use SIRTURO safely and effectively. See full prescribing information for SIRTURO. SIRTURO ®(bedaquiline) tablets, for oral use Initial U.S. Approval: 2012
Medication labelWhy this: Advisory · dailymed-prescription
SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (2 years and older and weighing at least 8 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampin and isoniazid. Limitations of Use Do not use SIRTURO for the treatment of: Latent infection due to Mycobacterium tuberculosis ( M. tuberculosis) Drug-sensitive pulmonary TB Extra-pulmonary TB Infections caused by non-tuberculous mycobacteria
- generic_name
- bedaquiline fumarate
- product_names
- Bedaquiline Fumarate
- ndc
- 59676-701, 59676-702, 59676-701-01, 59676-702-60
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en